PLSE (Pulse Biosciences) EBIT: $-78.05 Mil (TTM As of Mar. 2026)

What is Pulse Biosciences EBIT?

Pulse Biosciences PLSE +7.44% 31 EBIT is $-78.05 Mil as of Mar. 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Pulse Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-19.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-78.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pulse Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 was -509.46%. Pulse Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,111.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pulse Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.24%.

Pulse Biosciences (NAS:PLSE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pulse Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-76.6 * ( 1 - 0% )	/	( (14.667	+	15.404)	/ 2 )
=	-76.6	/	15.0355
=	-509.46 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	94.539	-	4.374	-	( 80.735	-	max(0, 7.923	-	83.421	+	80.735	))
=	14.667

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	81.622	-	4.884	-	( 68.319	-	max(0, 9.796	-	71.13	+	68.319	))
=	15.404

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pulse Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-76.6	/	( ( (7.061 + max(-3.667, 0))	+	(6.718 + max(-5.358, 0)) )	/	2 )
=	-76.6	/	( ( 7.061	+	6.718 )	/	2 )
=	-76.6	/	6.8895
=	-1,111.84 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.274	+	0.136	+	2.276)	-	(4.374	+	0	+	1.979)
=	-3.667

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.157	+	0.206	+	2.448)	-	(4.884	+	0	+	3.285)
=	-5.358

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pulse Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-78.045	/	1842.448
	=	-4.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulse Biosciences EBIT Related Terms

Pulse Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Pulse Biosciences's EBIT can be seen below:

Pulse Biosciences EBIT Chart

Pulse Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-63.01

-58.06

-43.57

-56.26

-76.94

Pulse Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-18.04	-20.28	-20.37	-18.25	-19.15

PLSE vs NNNN, STAA, ATRC: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulse Biosciences EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's EV-to-EBIT falls into.

Save Embed

31GF Score

Pulse Biosciences Inc PLSE

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pulse Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.05 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-78.05 Mil mean?

Pulse Biosciences (PLSE) has a EBIT of $-78.05 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pulse Biosciences.

Is Pulse Biosciences' EBIT too high?

Pulse Biosciences' current EBIT is $-78.05 Mil. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Pulse Biosciences' EBIT compare to NNNN and STAA?

Pulse Biosciences' EBIT of $-78.05 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pulse Biosciences. Pulse Biosciences's current EBIT is $-78.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pulse Biosciences stock overvalued right now?

Pulse Biosciences (PLSE) has a current EBIT of $-78.05 Mil. The current EBIT is $-78.05 Mil. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current EBIT is $-78.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pulse Biosciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies NNNN STAA ATRC XRAY LMAT KMTS BLFS AZTA ANGO WRBY ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges 6L8:Germany

Address 601 Brickell Key Drive, Suite 1080, Miami, FL, USA, 33131

Website https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

31GF Score

Get the complete analysis for PLSE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.51

Price

View PLSE Analysis

See EBIT data for all stocks →